Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q3 FY23 results · Oct–Dec 2022
Bliss GVS Pharma reported revenue from operations of ₹205.72 crore (down 4.9% from Q3 FY22) and net profit of ₹29.79 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 205.72 | 216.26 | −4.9% | 172.43 | +19.3% |
| Other income | 5.65 | 6.04 | −6.5% | 2.15 | +162.5% |
| Total income | 211.36 | 222.29 | −4.9% | 174.58 | +21.1% |
| Profit before tax | 47.43 | (38.86) | Turned profit | 20.19 | +134.9% |
| Net profit for the period | 29.79 | (48.53) | Turned profit | 16.00 | +86.2% |
| Attributable to shareholders of the company | 27.94 | (50.11) | Turned profit | 13.85 | +101.7% |
| EPS, basic (₹) | 2.68 | (4.83) | Turned profit | 1.33 | +101.5% |
| Net margin (%) | 14.5 | -22.4 | 9.3 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.79 | 190.60 | −11.4% | 138.85 | +21.6% |
| Other income | 11.42 | 6.31 | +81.0% | 14.23 | −19.7% |
| Total income | 180.21 | 196.91 | −8.5% | 153.08 | +17.7% |
| Profit before tax | 39.89 | 36.41 | +9.6% | 35.29 | +13.0% |
| Net profit for the period | 29.28 | 27.17 | +7.8% | 25.45 | +15.1% |
| EPS, basic (₹) | 2.81 | 2.62 | +7.3% | 2.45 | +14.7% |
| Net margin (%) | 17.3 | 14.3 | 18.3 |
Consolidated
- Filed with BSE
- 30 Jan 2023, 17:13 IST
- Board meeting
- 24 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2023, 17:13 IST
- Board meeting
- 24 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE